Immunotherapy combinations for the treatment of patients with solid tumors
| Autor: | Neus Basté, Maria Virginia Bluthgen, Gonzalo Recondo |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Cancer Research medicine.medical_treatment chemical and pharmacologic phenomena 03 medical and health sciences 0302 clinical medicine Immune system Neoplasms Antineoplastic Combined Chemotherapy Protocols medicine Humans Immune Checkpoint Inhibitors Chemotherapy Clinical Trials as Topic business.industry Standard treatment Cancer General Medicine Immunotherapy medicine.disease Prognosis Immune checkpoint Blockade 030104 developmental biology Oncology 030220 oncology & carcinogenesis Cancer cell Cancer research Drug Therapy Combination business |
| Zdroj: | Future oncology (London, England). 16(23) |
| ISSN: | 1744-8301 |
| Popis: | Immune checkpoint inhibitors directed against CTLA-4, PD-1 and PD-L1 have transformed the treatment of patients with cancer. Immunotherapy regimens have evolved from a single agent approach to the combination of immune checkpoint inhibitors like anti CTLA-4 and PD-1, immune checkpoint blockade combined with chemotherapy, anti-angiogenic agents and kinase inhibitors. These synergistic combinations were developed to heighten the potency and duration of immune responses against cancer cells. Hence, immunotherapy combinations have shaped the landscape of therapeutic options against a wide range of cancer types, and are current standard treatment regimens worldwide. In this review, we describe the clinical evidence supporting the use of immunotherapy combination regimens for the treatment of patients with solid tumors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|